Clinical experience of patients with hepatitis C virus infection among Australian GP trainees

Joshua S Davis, Amanda Tapley, Simon Morgan, Mieke L van Driel and Parker J Magin
Med J Aust 2017; 206 (7): . || doi: 10.5694/mja16.01106
Published online: 17 April 2017

Since March 2016, new direct-acting antiviral agents (DAAs) for treating infection with hepatitis C virus (HCV) have been available in Australia under the Pharmaceutical Benefits Scheme (PBS). This represents a revolution in the treatment of hepatitis C, as DAA regimens have cure rates of more than 90%, minimal adverse effects, and low treatment complexity. In contrast to previous HCV treatments, general practitioners are authorised to prescribe HCV DAAs. The Fourth National HCV Strategy emphasises that, to maximise the impact of HCV DAAs, most HCV treatment will need to move from hospital-based clinics to the primary care setting.1

  • Joshua S Davis1,2
  • Amanda Tapley3
  • Simon Morgan4
  • Mieke L van Driel5
  • Parker J Magin6

  • 1 Menzies School of Health Research, Darwin, NT
  • 2 John Hunter Hospital, Newcastle, NSW
  • 3 GP Synergy, Sydney, NSW
  • 4 Elermore Vale General Practice, Newcastle, NSW
  • 5 The University of Queensland, Brisbane, QLD
  • 6 University of Newcastle, Newcastle, NSW


Competing interests:

Joshua Davis has previously received research funding from Gilead Sciences and Abbvie for viral hepatitis-related research, but not for the study reported in this article.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.